Rotavirus Vaccination Is Associated With Reduced Seizure Hospitalization Risk Among Commercially Insured US Children

Rachel M. Burke, Jacqueline E. Tate, Rebecca Moritz Dahl, Negar Aliabadi, and Umesh D. Parashar

Division of Viral Diseases, Epidemic Intelligence Service, and MAXIMUS Federal, contracting agency to the Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

Rotavirus commonly causes diarrhea but can also cause seizures. Analysis of insurance claims for 1,773,295 US children with 2950 recorded seizures found that, compared to rotavirus-unvaccinated children, seizure hospitalization risk was reduced by 24% (95% confidence interval [CI], 13%–33%) and 14% (95% CI, 0%–26%) among fully and partially rotavirus-vaccinated children, respectively.

Keywords. rotavirus; rotavirus vaccine; immunizations; seizures; pediatric gastroenteritis.

Before vaccine implementation, rotavirus was associated with approximately 70%–80% [2]. Two rotavirus vaccines are currently recommended by the Advisory Committee on Immunization Practices: pentavalent RotaTeq (RV5; Merck and Company), given at 2, 4, and 6 months of age; and monovalent Rotarix (RV1; GlaxoSmithKline Biologics), given at 2 and 4 months of age [3].

Rotavirus disease has also been associated with extraintestinal symptoms. Seizures, particularly benign afebrile convulsions, are the most commonly described [4]. This observation has led to the hypothesis that rotavirus vaccination, by preventing natural rotavirus infection, may have the added benefit of reducing seizure risk. A prior study found a significant protective effect of rotavirus vaccination on the 1-year seizure risk (18%–21% decrease) in a retrospective cohort of US children [5]. In Australia, rotavirus vaccination status was significantly lower in children hospitalized for seizure as compared to the overall catchment population [6]. Furthermore, recent ecological analyses from the United States and Spain have both demonstrated decreases in annual seizure hospitalization rates (decreases of 1%–8% in the United States and 16%–34% in Spain) among children <5 years of age following implementation of rotavirus vaccination [7, 8], although a separate ecological analysis in Spain’s Valencia region did not find a significant effect [9]. However, ecological analyses are prone to several biases, and data are lacking regarding the longer-term impact of rotavirus vaccination on individual seizure risk. We utilized administrative claims data to determine differences in seizure hospitalization risk by rotavirus vaccination status among commercially insured US children <5 years of age.

METHODS

Data for 2006–2014 were abstracted from the Truven Health MarketScan Commercial Claims and Encounters database, which captures de-identified individual-level claims and encounter data from individuals <65 years of age enrolled in employer-sponsored commercial health insurance plans [10]. This database contains information on enrollment and medical claims for approximately 30–40 million employees and their beneficiaries from all 50 states. Medicaid recipients are not included. This analysis was not considered human subjects research.

For this analysis, the following eligibility criteria were applied: (1) child born on or after 1 January 2006 (birth date proxied using the date of the earliest delivery-related claim identified by the International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes V30–V39), to ensure eligibility for rotavirus vaccination, which was recommended for use in the United States in February 2006, with the first dose given at 2 months of age [3]; and (2) child continuously enrolled in the insurance plan since the month of birth, to ensure that all vaccination doses and all seizure events could be captured. Children were followed beginning from the month of birth. Rotavirus vaccination status and timing were calculated using the following Current Procedural Terminology codes: 90680 (RV5) and 90681 (RV1). Children were excluded from analysis if rotavirus vaccine dose 1 was given at <4 weeks, dose 2 at <6 weeks, or dose 3 at <8 weeks, or if the date of any previous dose was missing. The remaining children were classified as “unvaccinated” as long as they had not received any dose of any rotavirus vaccine. Once a child received a single dose of either RV1 or RV5, they were reclassified as “partially vaccinated.” Children were reclassified as “fully vaccinated” once they had received 2 doses of RV1 or 3 doses of RV5. Seizures were defined based on hospitalization discharge ICD-9-CM codes 333.2*, 345*, 779.0*,
and 780.3*; only seizure codes in the first diagnostic position were included in the analysis, and if multiple seizure-related hospitalizations occurred over the study period, only the first was analyzed. In the absence of a seizure event, children were censored at 60 months or when no longer enrolled, whichever came first. For the primary analysis, only children surviving until at least 27 weeks of age without a seizure hospitalization were included. Furthermore, because completely unvaccinated children may differ from those who receive routine immunizations, we excluded children who had not received any doses of vaccines containing diphtheria, pertussis, and tetanus antigens (DTaP) by the age of 6 months.

Survival analysis was employed using time to first seizure as the outcome, and age (in weeks) as the time scale. The time-varying nature of the exposure (vaccination status) was accounted for by analyzing data in the counting process format and using extended Cox regression. The model included rotavirus vaccination status as the (time-varying) exposure and controlled for year of birth (to account for secular changes in rotavirus vaccine coverage and rotavirus circulation) and receipt of DTaP vaccine doses (also time-varying); robust standard errors were calculated and used to generate 95% confidence intervals (CIs). Multiple sensitivity analyses were done. These are described in the Supplementary Materials. Data were cleaned and analyzed using SAS version 9.4 (Cary, North Carolina) and the R Environment for Statistical Computing software.

RESULTS

Overall, 1,773,295 children were eligible for analysis, among whom 2950 seizures were recorded (654 of these were before 6 months of age and were not included in the primary analysis); the estimated 5-year risk was 0.35% (95% CI, .34–.36). Among the 1,193,425 children followed until at least 6 months of age without a seizure hospitalization and receiving at least 1 dose of DTaP, 848,869 (71.1%) were fully vaccinated, 176,350 (14.8%) were partially vaccinated, and 168,206 (14.1%) were unvaccinated against rotavirus. Most vaccinated children (887,251 [86.5%]) had received RV5.

Examination of the unadjusted survival curve showed a reduced risk of seizure among fully vaccinated children, compared to unvaccinated or partially vaccinated children (Figure 1).

Extended Cox regression models gave a crude hazard ratio of 0.66 (95% CI, .60–.72) comparing fully vaccinated to unvaccinated children, and 0.88 (95% CI, .78–1.01) comparing partially vaccinated to unvaccinated children. Hazard ratios were slightly attenuated after adjusting for year of birth and receipt of DTaP vaccine doses: 0.76 (95% CI, .67–.87) for full vaccination and 0.86 (95% CI, .74–1.00) for partial vaccination, compared with unvaccinated children. Results were very similar across all sensitivity analyses, though the effect of partial rotavirus vaccination was significant in analyses using any-position seizure diagnostic codes (Supplementary Table 1).

DISCUSSION

We found that full rotavirus vaccination, compared with no rotavirus vaccination, was associated with a 24% reduction in seizure hospitalization hazard among commercially insured US children <5 years of age. This observation is consistent with a prior analysis using the Vaccine Safety Datalink dataset, which found an 18%–21% risk reduction in 1-year seizure risk among fully rotavirus-vaccinated US children, compared to unvaccinated children followed up to 1 year after vaccination [5].

Our analysis, demonstrating the beneficial impact of rotavirus vaccination on seizure hospitalization risk in the first 5 years of life, is the first to address this association in a cohort of children followed for >1 year after rotavirus vaccination. The large amount of data in the MarketScan database enhanced the power of this analysis, enabling us to detect significant differences in seizure hospitalization risk despite the rarity of this event. Furthermore, the similarity of results from multiple sensitivity analyses lends confidence to our findings. The fact that

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Unadjusted seizure hospitalization survival curve, by vaccination status. Seizure survival was highest for children fully vaccinated against rotavirus (green), as compared to partially vaccinated (yellow) or unvaccinated (red) children.
results were nearly identical when excluding children born in universal vaccination states is reassuring regarding the potential impact of misclassifying vaccination status in these states. Moreover, even if additional misclassification of vaccination status occurred (for instance, if rotavirus immunizations were received outside the child’s insurance network), it is most likely that vaccinated children would have been classified as unvaccinated; this would bias results toward the null. Similarly, results excluding or controlling for preterm children show that confounding by gestational age is likely minimal or toward the null. Sensitivity analyses where we lagged the time of vaccination by 4 weeks also provided additional evidence regarding biological plausibility. First, the introduced lag time allowed for an immunologic response to rotavirus vaccination. Second, the lag time helped to mitigate spurious associations between vaccination and seizure, for instance, febrile seizures related to concurrent vaccination with other vaccines (eg, pneumococcal vaccine). The sensitivity analyses using seizure diagnostic codes in any position also helped to account for a potential lack of sensitivity of first-position seizure diagnostic codes. Restricting to children surviving until at least 6 months of age without a seizure hospitalization also may have helped to maximize the specificity and positive predictive value of the ICD-9-CM codes used to identify seizures, though an analysis including children from birth gave similar results.

The present analysis is subject to the following limitations. Although the MarketScan database is representative of the US population that receives health insurance through employer-sponsored plans, the database does not include individuals covered by Medicaid or non-employer-sponsored insurance plans. The study population may therefore not be representative of all US children, and may exhibit differences in immunization-related factors. Second, we did not have sufficient data to control for all possible confounders, and so our results may be subject to residual confounding. However, the apparent dose-response pattern lends biological plausibility to our findings. Third, because of the rare nature of seizure discharges, we were subject to residual confounding. However, they have been shown to have a high positive predictive value in the inpatient setting, particularly for first-time seizures [11], and any misclassification of seizure status would likely be nondifferential, thus biasing results toward the null.

Despite its limitations, the present study provides compelling data to suggest that rotavirus vaccination, in addition to preventing diarrheal morbidity, also has significant benefits on seizure risk in children. A seizure hospitalization presents not only substantial cost and morbidity [12, 13], but also causes important emotional trauma to the child and family. Reduction in seizure hospitalization risk is an important added benefit of rotavirus vaccination and supports continued universal rotavirus vaccination in the United States.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyrighted and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Disclaimer. The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Potential conflicts of interest. All authors: No potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References